CytomX Therapeutics (CTMX) Cash from Operations Growth (1y) (2015 - 2026)

CytomX Therapeutics (CTMX) Cash from Operations Growth (1y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 7.14%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 356.73%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 74.39%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.23%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 CytomX Therapeutics 590.32 Mn 243.61 Mn - -21.41%

Historic Data

Download Data
DateValue
Mar 31, 2026 -21.41%
Dec 31, 2025 -16.75%
Sep 30, 2025 24.99%
Jun 30, 2025 19.42%
Mar 31, 2025 19.21%
Dec 31, 2024 9.36%
Sep 30, 2024 -13.63%
Jun 30, 2024 22.36%
Mar 31, 2024 -378.59%
Dec 31, 2023 -1,476.67%
Sep 30, 2023 46.10%
Jun 30, 2023 26.46%
Mar 31, 2023 122.63%
Dec 31, 2022 95.53%
Sep 30, 2022 -13.96%
Jun 30, 2022 -21.41%
Mar 31, 2022 -37.99%
Dec 31, 2021 -78.99%
Sep 30, 2021 -20.35%
Jun 30, 2021 -129.04%